At a time when the biotech sector has been struggling with a lack of investment, some companies have had to make decisions to change trial designs, whether that be reducing the number of patients or changing the observation times. Speaking during a fireside chat at Swiss Biotech Day 2025, which took place 5–6 May in Basel, Houman Ashrafian, executive vice president and head of Research and Development (R&D) at Sanofi, said that while it may seem a good idea to “squeeze a clinical trial” to keep a company running for longer, this could end up shutting the company down even quicker. “Don't mess up the clinical trial. It's critically important…Doing the wrong trial with your asset will kill it very quickly.” In the case of some trial failures, an additional $3–$4m investment to power the trial correctly and run it efficiently, could have led to transformative results, he said. “There are companies that are on the public markets who recently announced trials that came within a p-value of 0.07, and it tanked their share price. If they had run the trial for two more months and enrolled five, maybe 10 more patients, it could have been very different.” While some companies have been struggling to balance their finances, Ashrafian believes that it is not a completely negative thing that biotech has had to tighten its belts since the 2021 boom, as some companies made very surprising financial decisions at that time. “We went through years where biotech got better and better funding. Preclinical companies received vast amounts of revenue and some even went public. For me, that is the definition of madness where you expose yourself like that, but I was also one of those. The lure of liquidity meant that we wanted to rush [to] the public market. Those companies were the first ones to experience real pain when there was scrutiny,” Ashrafian said. Sanofi has a venture capital (VC) arm, which provides funding to biotechs to run clinical trials. Ashrafian invited biotech companies to look into such options to ensure they run the most effective trial to get their asset through early stages of development, after which a pharmaceutical company could pick it up to complete the final development. “Biotech produces molecules at a significant discount to pharma. Chemistry, Manufacturing, and Controls (CMC) may not be as good, but biotech [companies] get the molecule through Phase I, and they do that beautifully. But actually, the trial that determines the exit financing round is often not done as well. That’s where we come in with finance and expertise,” concluded Ashrafian. Story Continues Note: Some travel expenses that allowed the Clinical Trials Arena reporter to attend the Swiss Biotech Day conference were covered by the investment agency Switzerland Global Enterprise. "Sanofi exec tells biotechs not to scrimp on clinical trial design" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
Sanofi exec tells biotechs not to scrimp on clinical trial design
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...